title: [A case of hepatocellular carcinoma rapidly progressing after percutaneous radiofrequency ablation successfully treated with low-dose 5-FU and CDDP].
abstract: A 65-year-old Japanese man was admitted to our hospital for treatment of hepatocellular carcinoma (HCC) with alcoholic liver cirrhosis. He had been treated by transarterial chemoembolization (TACE) in another hospital before this admission. In our hospital, percutaneous radiofrequency ablation (PRFA) to HCC (2.5 cm diameter) in hepatic S8 was done, and the tumor was ablated completely with the treated margin. After 8 months of the PRFA procedure, abdominal CT revealed diffused-type HCC located in contact with the post RFA area and was diagnosed as a local recurrence of HCC. He was then treated with hepatic arterial infused chemotherapy, low-dose 5-FU and CDDP (FP); one course consisted of (5-FU 250 mg/day + CDDP 10 mg/day) x 5 days/w x 4 wks using a port-infusion system. He was treated with 3 courses of low-dose FP, and the diffuse-type HCC was completely diminished. No recurrence was seen 22 months after chemotherapy. Although rapidly progressing recurrent HCC after PRFA is potentially fatal and useful treatments have only rarely been reported, hepatic arterial infusion chemotherapy including low-dose FP should be considered a possible treatment.
authors.affiliation: Third Dept. of Internal Medicine, University of Toyama.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yata
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Nakayama
authors.forename: Katsuharu
authors.initials: K
authors.lastname: Hirano
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Tokimitsu
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kudo
authors.forename: Kengo
authors.initials: K
authors.lastname: Kawai
authors.forename: Shinya
authors.initials: S
authors.lastname: Kajiura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yasumura
authors.forename: Masami
authors.initials: M
authors.lastname: Minemura
authors.forename: Terumi
authors.initials: T
authors.lastname: Takahara
authors.forename: Toshiro
authors.initials: T
authors.lastname: Sugiyama
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D017115:Catheter Ablation; D002945:Cisplatin / Q000627:therapeutic use*; D018450:Disease Progression; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D008297:Male; D012074:Remission Induction; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D000509:alpha-Fetoproteins; D002945:Cisplatin; D005472:Fluorouracil